Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations

JA Seidel, A Otsuka, K Kabashima - Frontiers in oncology, 2018 - frontiersin.org
Melanoma, a skin cancer associated with high mortality rates, is highly radio-and
chemotherapy resistant but can also be very immunogenic. These circumstances have led to …

Immune-related adverse events of immune checkpoint inhibitors: a review

Q Yin, L Wu, L Han, X Zheng, R Tong, L Li… - Frontiers in …, 2023 - frontiersin.org
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised …

AG Sacco, R Chen, FP Worden, DJL Wong… - The Lancet …, 2021 - thelancet.com
Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …

PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome

HO Alsaab, S Sau, R Alzhrani, K Tatiparti… - Frontiers in …, 2017 - frontiersin.org
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …

Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study

N Daver, G Garcia-Manero, S Basu, PC Boddu… - Cancer discovery, 2019 - AACR
Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …

Small‐molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery

G Li, B Sun, Y Li, C Luo, Z He, J Sun - Small, 2021 - Wiley Online Library
The antitumor efficiency and clinical translation of traditional nanomedicines is mainly
restricted by low drug loading, complex preparation technology, and potential toxicity …

Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

MZ Wojtukiewicz, MM Rek, K Karpowicz… - Cancer and Metastasis …, 2021 - Springer
The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

W Zou, JD Wolchok, L Chen - Science translational medicine, 2016 - science.org
Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …

Targeting natural killer cells in cancer immunotherapy

C Guillerey, ND Huntington, MJ Smyth - Nature immunology, 2016 - nature.com
Alteration in the expression of cell-surface proteins is a common consequence of malignant
transformation. Natural killer (NK) cells use an array of germline-encoded activating and …

Immunological effects of conventional chemotherapy and targeted anticancer agents

L Galluzzi, A Buque, O Kepp, L Zitvogel, G Kroemer - Cancer cell, 2015 - cell.com
The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …